Skip to main content

Main menu

  • Home
  • Content
    • Early Access
    • Current Issue
    • Kidney360 Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
  • Clinical Images
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • More
    • About Kidney360
    • Advertising
    • Disqus Commenting
    • Reprint Information
    • Feedback
    • Email Alerts
  • ASN Kidney News
  • Other
    • JASN
    • CJASN
    • Kidney News Online
    • American Society of Nephrology

User menu

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • CJASN
    • Kidney News Online
    • American Society of Nephrology
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Early Access
    • Current Issue
    • Kidney360 Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
  • Clinical Images
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • More
    • About Kidney360
    • Advertising
    • Disqus Commenting
    • Reprint Information
    • Feedback
    • Email Alerts
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow Kidney360 on Twitter
  • Community Forum
  • Kidney360 RSS
Original Investigation

Focal Segmental Glomerulosclerosis, Risk Factors for End Stage Kidney Disease, and Response to Immunosuppression

Benjamin M. Forster, Robert Nee, Dustin J. Little, Peter J. Greasley, James B. Hughes, Sarah M. Gordon and Stephen W. Olson
Kidney360 December 2020, 10.34067/KID.0006172020; DOI: https://doi.org/10.34067/KID.0006172020
Benjamin M. Forster
1Walter Reed National Military Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Nee
2Nephrology, Walter Reed National Military Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Nee
Dustin J. Little
3AstraZeneca, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dustin J. Little
Peter J. Greasley
4AstraZeneca, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter J. Greasley
James B. Hughes
1Walter Reed National Military Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah M. Gordon
1Walter Reed National Military Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen W. Olson
2Nephrology, Walter Reed National Military Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: stephen.w.olson.mil@mail.mil
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Background: Focal segmental glomerulosclerosis (FSGS) is a heterogeneic glomerular disease. Risk factors for end- stage kidney disease (ESKD) and impact of immunosuppression treatment (IST) has varied in previously published cohorts. These cohorts were limited by relatively small case numbers, short follow up, lack of racial/ethnic diversity, a mix of adult and pediatric patients, lack of RAAS inhibition, or lack of subgroup analysis of IST. Methods: We compared demographics, clinical characteristics, histopathology and IST to long term renal survival in a large, ethnically diverse, adult cohort of 338 biopsy-proven FSGS cases with long term follow up in the era of RAAS inhibition using data from the United States Department of Defense health care network. Results: Multivariate analysis showed that nephrotic range proteinuria (NRP), estimated glomerular filtration rate <60 ml/min/1.73m2, hypoalbuminemia, interstitial fibrosis and tubular atrophy, and interstitial inflammation at diagnosis as well as the absence of remission were all associated with worse long term renal survival. IgM, C3, and a combination of IgM/C3 immunofluorescence staining were not associated with reduced renal survival. IST was not associated with improved renal survival in the whole cohort, or in a subgroup with NRP. However, IST was associated with better renal survival in a subgroup of FSGS cases with both NRP and hypoalbuminemia and hypoalbuminemia alone. Conclusion: Our study suggests that IST should be reserved for FSGS patients with nephrotic syndrome. It also introduces interstitial inflammation as a potential risk factor for ESKD and does not support the proposed pathogenicity of IgM and complement activation.

  • Focal Segmental Glomerulosclerosis
  • End Stage Kidney Disease
  • Immunosuppression
  • Renal Survival
  • Risk Factors
  • Proteinuria
  • estimated glomerular filtration rate
  • Received October 14, 2020.
  • Revision received November 30, 2020.
  • Accepted November 30, 2020.
  • Copyright © 2020 American Society of Nephrology
PreviousNext
Back to top

In this issue

Kidney360: 1 (12)
Kidney360
Vol. 1, Issue 12
31 Dec 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Download PDF
Sign up for Alerts
Email Article

Thank you for your interest in spreading the word on American Society of Nephrology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Focal Segmental Glomerulosclerosis, Risk Factors for End Stage Kidney Disease, and Response to Immunosuppression
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
FSGS risk factors and treatment
Benjamin M. Forster, Robert Nee, Dustin J. Little, Peter J. Greasley, James B. Hughes, Sarah M. Gordon, Stephen W. Olson
Kidney360 Dec 2020, 10.34067/KID.0006172020; DOI: 10.34067/KID.0006172020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
FSGS risk factors and treatment
Benjamin M. Forster, Robert Nee, Dustin J. Little, Peter J. Greasley, James B. Hughes, Sarah M. Gordon, Stephen W. Olson
Kidney360 Dec 2020, 10.34067/KID.0006172020; DOI: 10.34067/KID.0006172020
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Performance-based functional assessments in CKD
  • Association between IgM and childhood SRNS
  • Microbiome and p-Inulin in Hemodialysis
Show more Original Investigation

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Google Scholar

Keywords

  • focal segmental glomerulosclerosis
  • end stage kidney disease
  • immunosuppression
  • renal survival
  • risk factors
  • proteinuria
  • estimated glomerular filtration rate

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • Kidney360
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About Kidney360
  • Kidney360 Email Alerts
  • Kidney360 Podcasts
  • Kidney360 RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Disqus Code of Conduct
  • Disqus Information
  • Feedback
  • Follow on Twitter
  • Subscribe to JASN and CJASN

© 2021 American Society of Nephrology

Online ISSN - 2641-7650

Powered by HighWire